DNA Microarray Profiling to Identify Angiotensin-Responsive Genes in Vascular Smooth Muscle Cells
- 10 January 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 92 (1), 111-118
- https://doi.org/10.1161/01.res.0000049100.22673.f6
Abstract
Angiotensin II (Ang II) induces changes in vessel structure by its capacity to activate genes that are coupled to signaling pathways such as extracellular signal–regulated kinase (ERK), p38, and phosphatidylinositol 3-kinase (PI3K). Using a DNA microarray containing 5088 genes and expressed sequence tags, we initially established a database of replicated experiments (n=4) to define the variances in mRNA expression in response to Ang II versus vehicle treatment. We observed a wide range of values for the coefficients of variation in a gene-specific manner. Guided by power calculations, we used statistical inference on a sufficient number of experimental replicates to minimize the number of false-negatives and define a subset of Ang II–responsive genes (P<0.05). To further characterize the molecular circuitry that couples Ang II stimulation with mRNA expression, we assessed expression profiles in the presence and absence of inhibitors of ERK, p38, and PI3K. Using two different methods of computational cluster analysis, we identified a subset of six matricellular proteins (eg, osteopontin and plasminogen activator inhibitor-1) that are coordinately upregulated by Ang II via an ERK/p38-dependent pathway. In addition, these cluster analyses identified calpactins I and II as novel Ang II–responsive genes. Given that Ang II promotes vascular lesion formation, we examined whether this matricellular gene cluster was also coordinately regulated in vivo. Indeed, we demonstrate that both calpactin I and osteopontin are upregulated in response to vascular injury. Taken together, the combined use of DNA microarrays, statistical inference, and cluster analysis identified novel, coordinately regulated Ang II–responsive genes that may mediate vascular lesion formation.Keywords
This publication has 15 references indexed in Scilit:
- Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP‐mediated suppression of ERK phosphorylation and AML1B nuclear partitioningThe FASEB Journal, 2000
- Reactive Oxygen Species Mediate the Activation of Akt/Protein Kinase B by Angiotensin II in Vascular Smooth Muscle CellsJournal of Biological Chemistry, 1999
- The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and HypertensionNew England Journal of Medicine, 1998
- Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.Journal of Clinical Investigation, 1994
- Elastin synthesis is inhibited by angiotensin II but not by platelet-derived growth factor in arterial smooth muscle cellsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1994
- Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.Journal of Clinical Investigation, 1993
- Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.Proceedings of the National Academy of Sciences, 1993
- Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.Journal of Clinical Investigation, 1993
- Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cellsBiochemical and Biophysical Research Communications, 1992
- Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.Journal of Clinical Investigation, 1992